Learn how PLUVICTO, the first and only radioligand therapy (RLT) for PSMA+ mCRPC, works as a targeted treatment. See full Prescribing and Safety Info.
ATNM-400 is a highly innovative, first-in-class prostate cancer candidate in comparison to Pluvicto and the majority of radiotherapies in development for prostate cancer which target PSMA and are ...
Precision Medicine Online: Novartis Withdraws EMA Application for Pluvicto in Earlier-Line PSMA-Positive Prostate Cancer
What is PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan)? PLUVICTO is a prescription treatment used to treat adults with prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) already treated with: hormone therapy and are considered appropriate to delay chemotherapy or
Find a list of answers to frequently asked questions about PSMA+ mCRPC and treatment with PLUVICTO. See full Prescribing and Safety Info.
View the response to treatment with PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan) injection in two clinical studies. See full Prescribing & Safety Info.
Learn if PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan) treatment could be next for your PSMA+ mCRPC. See full Prescribing and Safety Info.
Find resources for patients on their treatment journey with PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan) injection. See full Prescribing & Safety Info.
Find information about the side effects of treatment with PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan) injection. See full Prescribing & Safety Info.
Hear stories from patients and their loved ones about their PSMA+ mCRPC treatment journey with PLUVICTO. See full Prescribing and Safety Information.
Nasdaq: Actinium Presents Data Showing ATNM-400 is More Efficacious than Pluvicto and is Highly Efficacious after Pluvicto Resistance in Prostate Cancer Tumor Models at the American ...